Patterns and factors associated with dose escalation during maintenance treatment for inflammatory bowel disease: a population-based cohort study.

Remicade (infliximab) - J&J

Humira (adalimumab) - AbbVie

tofacitinib - Generic mfg.

Stelara (ustekinumab) - J&J

Entyvio (vedolizumab) - Takeda

http://www.ncbi.nlm.nih.gov/pubmed/42775158

Dahye Ryu; Hae Sun Suh; Hyun Jin Han; Junghyun Na; Seoyeon Choi; Young Mi Park

Sep 24, 2026